ANTICANCER DRUG COMPRISING CYCLIC RGD SEQUENCE-CONTAINING PEPTIDE
|Posted date||Mar 19, 2015|
|International application number||2013JP082272|
|International publication number||WO 2014084378|
|Date of international filing||Nov 29, 2013|
|Date of international publication||Jun 5, 2014|
|Title||ANTICANCER DRUG COMPRISING CYCLIC RGD SEQUENCE-CONTAINING PEPTIDE|
|Abstract||Provided is an anticancer drug which has advantages such as reduced gastrointestinal toxicity and less weight loss in patients. This anticancer drug comprises an anti-cancer active ingredient and a cyclic arginine-glycine-aspartic acid (RGD) sequence-containing peptide.|
|Outline of related art and contending technology||
Anti-cancer chemotherapy is a major option in cancer treatment, many anti-cancer active ingredient is, nontoxic to normal cells as well as tumor cells affect, the risk of side effects. In particular, conventional low molecule anti-cancer active ingredient, as well as a target tumor lesion, other normal tissue, and the organs on the drugs also widely distributed, metabolism and blood for a relatively short residence time, to maintain an effective concentration at the target site difficult. Accordingly, quantities of drug must be administered repeatedly tend, with which the possibility of an occurrence of side effects such as weight loss higher than the.
For this reason, from the viewpoint of reducing side effects, locally to the site to target anticancer drug delivery system for efficient delivery (Drug Delivery System: DDS) is, has been proposed.
For example, by a part of the inventors of the present invention (Japanese Patent Application Laid-Open 8-188541) patent document 1 is, uncharged segment and a charged segment of the block copolymer obtained by self-organization, capacitive coupling disclosed polymeric micelle type drug carrier.
In addition, the present inventors also part of the patent document 2 (International Publication No. 2005/056641 pamphlet) is, the above-described configuration of the capacitive coupling type polymeric micelle drug carrier, diaminocyclohexane platinum (II) activity of anti-tumor ingredient disclosed an anti-tumor agent.
In addition, a part of the inventors of the present invention also Patent Document 3 (pamphlet of International Publication No. 2006/118260) is, uncharged hydrophilic segments having a cationic segment and a block copolymer of 1 (for example PEG - polycation or the like) and, uncharged hydrophilic segment 2 having a first segment and an anionic block copolymer (for example PEG - polyanion or the like) obtained by self-organization and, capacitive coupling-type polymer vesicles disclosed drug carrier.
On the other hand, the non-patent document 1(Nasongkla et al., Nano Letters, (2006), 6, 11, 2427-30), doxorubicin-containing polymeric micelle cRGD peptide may be coupled to the hydrophilic block, improved anti-cancer effects reported.
|Scope of claims||
(In Japanese)請求の範囲 [請求項1]
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
Contact Information for " ANTICANCER DRUG COMPRISING CYCLIC RGD SEQUENCE-CONTAINING PEPTIDE "
- CASTI TODAI TLO
- URL: https://todaitlo.com/en/
- Address: UCR Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan ,
- Fax: 03-5805-7699